A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
Фаза 2 – изследване на ефективността и дозировката
Заболявания:
Type 2 Diabetes Mellitus (T2DM)
Спонсор: Alnylam Pharmaceuticals
Налично на:
БГ
Обобщение
The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DM
Кой може да участва
Inclusion Criteria:
* Is an adult patient with a confirmed diagnosis of T2DM
* Has a body mass index (BMI) of ≥25 kg/m\^2 and \<39.9 kg/m\^2
* Has a hemoglobin A1c (HbA1c) ≥6.5% to \<10.5%
* Is on a stable dose of metformin
Exclusion Criteria:
* Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise participant safety or confound interpretation of study results
* Receiving therapies known to interfere with glucose or insulin metabolism other than current treatment for T2DM or birth control methods
Note: other protocol defined inclusion/exclusion criteria apply